Stereotactic Ablative Radiotherapy
Stereotactic Ablative Radiotherapy is a medical procedure with 35 clinical trials. Currently 19 active trials ongoing. Historical success rate of 75.0%.
Success Metrics
Based on 3 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
8
Mid Stage
6
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
60.0%
3 of 5 finished
40.0%
2 ended early
19
trials recruiting
35
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer
Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Prostate Cancer Subclinical Metastatic Ablative MR-guided Radiotherapy
Clinical Trials (35)
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer
Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Prostate Cancer Subclinical Metastatic Ablative MR-guided Radiotherapy
SABR for Renal Tumors
Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors
Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer
Stereotactic Ablative Body Radiotherapy (SABR) With Maintenance of Systemic Therapy Versus Physicians' Choice of Systemic Therapy for Oligoprogressive ER-positive, Her-2 Negative Breast Cancer II
StereoTactic Ablative RadioTherapy of Cardiac Arrhythmias
Stereotactic Ablative Radiotherapy (SABR) of Pelvis and Prostate Targets For High Risk Prostate Cancer
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.
Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc
Total RadIoTherapy of Oligometastatic caNcerS
Stereotactic Ablative Radiotherapy for Comprehensive Treatment of 4-10 Oligometastatic Tumors
Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease
Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer
Stereotactic Ablative Radiotherapy for the Treatment of Refractory Ventricular Tachycardia
NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma
Drug Details
- Intervention Type
- PROCEDURE
- Total Trials
- 35